2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Pathology, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Non-Hodgkin Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

5356 Chidamide in combination with azacitidine, mitoxantrone liposome, and prednisone (CAMP regimen) in treatment-naïve TFH-derived peripheral T-cell lymphoma

Huimin Liu, ZhuoXin Zhang Jr2, Wei LIU3, Yi Wang4, Rui Lv, MD5, Yan Xu, MD6, Weiwei Sui7, Shuhua Yi, DO8, Gang An, MD9, Lu-Gui Qiu, PhD10, Dehui Zou, MD11
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Objective: TFH-derived peripheral T-cell lymphomas (PTCL) are characterized by poor prognosis and the absence of a universally accepted standard-of-care regimen. In previous ASH abstract (abs25-7104), we presented the preliminary safety and efficacy of chidamide, azacitidine, mitoxantrone liposome, and prednisone (CAMP) combination in treatment-naïve TFH-derived PTCL. Updated analysis with an expanded patient cohort and extended follow-up are presented in this report, aiming to further evaluate the antitumor activity and tolerability of this novel regimen and to reinforce its potential as a new treatment option for this challenging disease.

Methods: This study is a multicenter, prospective phase II clinical trial (ID: IIT2023003), the main purpose of which is to investigate the safety and preliminary efficacy (objective response rate, ORR) of chidamide in combination with azacitidine, mitoxantrone liposome and prednisone (CAMP regimen) in treatment-naïve TFH-derived PTCL. Eligible patients received the CAMP regimen: chidamide 30 mg/day orally twice weekly; azacitidine 75 mg/m2 subcutaneously on days 1-7; mitoxantrone liposome 16 mg/m2 on day 1; and prednisone 60 mg/m2 on days 1-5, with each cycle lasting 28 days. Patients who achieved CR/PR after four to six cycles could choose to undergo autologous hematopoietic stem cell transplantation (ASCT), followed by chidamide maintenance for 2 years.

Results: A total of 54 treatment-naïve patients with TFH-derived PTCL were enrolled. Of these, 51.9% were male, with a median age of 62 (range, 54-67) years. Based on clinical and pathological assessments, Ann Arbor stage III-IV, B symptoms, extranodal involvement, and EBER positivity were identified in 94.4%, 46.3%, 75.9%, and 60% of patients, respectively; IPI score ≥3 and PIT ≥2 were assigned to 46.3% and 70.4%, respectively. The median number of treatment courses was 4 (range, 4-6), with a complete response (CR/CRu) rate of 79.6%, a partial response (PR) rate of 18.5% and an ORR of 98.1%. Among them, 10 patients (18.2%) underwent ASCT as consolidation therapy. At a median follow-up of 11.2 (95% CI: 8.9-13.5) months, the median progression-free survival (PFS) was 17.3 (95% CI: 6.4-28.2) months while the median overall survival (OS) was not reached. The estimated 2-year PFS and OS rates of all patients were 42% and 83%, respectively. In the ASCT subgroup, with a median follow-up of 15.4 (95% CI: 11.5-19.3) months, the estimated 2-year OS rate was 88.9%. Patients receiving CAMP regimen therapy experienced an 79.6% incidence of grade III-IV myelosuppression, which was reversible with supportive care. Twenty-nine patients (53.7%) developed infections, predominantly involving the pulmonary and urinary tracts, but all were successfully treated with active anti-infective therapy.

Conclusion: This updated analysis confirms that the CAMP regimen produces a high complete response rate with a controllable safety profile in treatment-naïve TFH-derived PTCL, suggesting its potential as a new treatment option for this disease. Further expansion of the cohort is warranted to confirm these findings.

Huimin Liu: No relevant conflicts of interest to declare.